Radovich Peter 4

What Happened

• Peter Radovich, President and COO of Mirum Pharmaceuticals (MIRM), converted vested performance restricted stock units (PRSUs) and reported an open‑market sale. On March 15, 2026 he exercised/converted PRSUs totaling 30,220 shares (two conversion entries of 7,220 and 23,000 shares). These derivative conversions show $0 exercise price, consistent with RSUs (no cash exercise cost). On March 16, 2026 he sold 16,515 shares in the open market at $91.98 each, netting $1,519,015.
• The filing indicates some shares were sold to cover tax withholding obligations related to the vesting (see footnote). The reported activity appears to be the conversion of award units into shares and a subsequent sale—commonly a tax‑related sale rather than a fresh cash purchase.

Key Details

• Transaction dates and prices:
  • Mar 15, 2026: Conversion/exercise of PRSUs — 7,220 and 23,000 shares (reported with $0 exercise price).
  • Mar 16, 2026: Open‑market sale — 16,515 shares at $91.98, proceeds $1,519,015.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: Each PRSU converts to one share on vesting.
  • F2: Shares were sold to cover tax withholding on vesting.
  • F3/F4: The PRSUs vest on staggered schedules (some vested 3/15/25 & 3/15/26; others vest 2/3 on 3/15/26 and 1/3 on 3/15/27).
• Filing timeliness: Form 4 was filed March 17, 2026 for transactions on March 15–16, 2026 (filed within the standard two‑business‑day window).

Context

• These entries reflect PRSU vesting/conversion (derivative to common shares) and a subsequent sale. The $0 exercise price and the footnote about tax withholding indicate this was a vesting event with shares sold to satisfy taxes rather than a cash exercise of stock options.
• Such sales tied to vesting/tax withholding are routine and do not by themselves indicate a change in insider sentiment.